Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer

Table 1 Interleukin-10 promoter polymorphism identified by PCR-RFLP analysis

Polymorphism	Primer sequence	Annealing temperature	Restriction enzyme	Allele size
IL-10-1082G/A	5′-CTCGCTGCA ACCCAACTGGC-3′	58°C	MnlI	A: 139 bp
	5′-TCTTACCTATCCCTACTTCC-3′			G: 106, 33 bp
IL-10-819C/T	5′-TCATTCTATGTGCTGGAGATGG-3′	59°C	Mae III	C: 125, 84 bp
	5′-TGGGGGAAGTGGGTAAGAGT-3′			T: 209 bp
IL-10-592C/A	5′-GTGAGCACTACCTGACTAGC-3′	58°C	RsaI	C: 412 bp
	5′-CCTAGGTCACAGTGACGTGG-3′			A: 175, 237 bp

Table 2 Genotype and allele frequencies of interleukin-10 promoter SNP in gastric cancer patients and controls

Genotypes/allele	Casesn (%)	Controlsn (%)	Adjusted OR (95% CI)1	P
IL-10-1082	234	243
AA	189 (80.4)	217 (89.3)	1
AG	39 (17.2)	23 (9.7)	1.9 (1.1-3.4)	0.019a
GG	6 (2.4)	3 (1.0)	2.4 (0. 6-9.4)	0.244
A	417 (89.1)	457 (94.0)	1
G	51 (10.9)	29 (6.0)	1.2 (0.6-3.2)	0.007a
IL-10-819
TT	99 (42.3)	109 (44.9)	1
TC	96 (41.0)	106 (43.6)	0.9 (0.7-1.6)	0.975
CC	39 (16.8)	28 (11.5)	1.6 (0.9-2.8)	0.145
T	294 (62.8)	324 (66.7)	1
C	174 (37.2)	162 (33.3)	1.2 (0.9-1.6)	0.221
IL-10-592
AA	99 (42.3)	109 (44.9)	1
AC	96 (41.0)	106 (43.6)	0.9 (0.7-1.6)	0.975
CC	39 (16.8)	28 (11.5)	1.6 (0.9-2.8)	0.145
A	294 (62.8)	324 (66.7)	1
C	174 (37.2)	162 (33.3)	1.2 (0.9-1.6)	0.221
Haplotype
ATA	282 (60.3)	314 (64.6)	1
ACC	135 (28.9)	143 (29.4)	1.1 (0.8-1.5)	0.731
GCC	39 (8.3)	19 (3.9)	2.3 (1.2-4.1)	0.005a
GTA	12 (2.5)	10 (2.1)	1.3 (0.6-3.2)	0.504

¹Adjusted for age, gender, and smoking status;

^aP < 0.05. OR: Odds ratio.

Table 3 Cox regression analysis of variables affecting prognosis in advanced gastric cancer patients

Variable	P	Hazard ratio	95% CI for hazard ratio
			Lower	Upper
IL-10-1082 genotype	0.815	1.2	0.8	1.7
IL-10-819/-592 genotype	0.671	1.1	0.5	1.9
Treatment method	0.426	1.4	0.9	2.3
Age	0.595	0.9	0.7	1.3
Stage	0.234	1.2	0.9	1.5
Histology	0.519	1.2	0.7	2.1